Questions: Pyrimidine Degradation

Question 1

A patient with DPD deficiency is given a standard dose of 5-fluorouracil (5-FU) for colorectal cancer. What is the most likely clinical consequence?

• A. The 5-FU will be ineffective because DPD is required to activate the prodrug
• B. The patient will develop gout-like symptoms from uric acid accumulation
• C. 5-FU will accumulate to toxic levels, causing severe or fatal toxicity
• D. The patient will excrete excess β-alanine in urine, causing kidney damage

Answer: (C)

DPD is responsible for degrading approximately 80% of administered 5-FU. In a patient with DPD deficiency, this clearance step is impaired, so 5-FU accumulates to concentrations far higher than intended. This causes severe toxicities including neutropenia, mucositis, and neurotoxicity — potentially fatal at standard doses. DPD does not activate 5-FU (option A); 5-FU is active as administered but must be cleared. This pharmacogenetic interaction is clinically critical, which is why DPD genotyping before 5-FU treatment is increasingly standard practice.

Question 2

How do the clinical consequences of pyrimidine degradation differ from those of purine degradation?

• A. Pyrimidine degradation produces uric acid, which can cause gout; purines are degraded to soluble amino acids
• B. Pyrimidines are degraded to soluble, non-toxic products; purines are degraded to uric acid, which can crystallize and cause gout
• C. Both pathways produce uric acid, but pyrimidine-derived uric acid is more soluble
• D. Pyrimidine degradation leads to hyperammonemia; purine degradation does not produce ammonia

Answer: (B)

This contrast is clinically important: purine degradation ends in uric acid — a sparingly soluble compound that can crystallize in joints (gout) or kidneys (kidney stones) when produced in excess. Pyrimidine degradation instead produces β-alanine (from uracil and cytosine) and β-aminoisobutyrate (from thymine), along with CO₂ and NH₃. These products are water-soluble and easily handled — β-alanine can enter the TCA cycle and β-aminoisobutyrate is excreted in urine. The distinct endpoints explain why disorders of pyrimidine catabolism do not cause gout.

Question 3

Cytosine is converted to uracil by deamination before entering the ring-opening steps of pyrimidine degradation.

• T. True
• F. False

Answer: True

The pathway effectively funnels all three pyrimidine bases into just two routes: uracil and thymine. Cytosine is deaminated to uracil first, so the ring-opening enzymes (dihydropyrimidine dehydrogenase, dihydropyrimidinase, and β-ureidopropionase) only need to handle two substrates. Uracil yields β-alanine, CO₂, and NH₃; thymine yields β-aminoisobutyrate, CO₂, and NH₃. This convergence simplifies the catabolic machinery needed.

Question 4

Pyrimidine degradation is clinically similar to purine degradation because both pathways produce poorly soluble end products that can accumulate in tissues.

• T. True
• F. False

Answer: False

This is false. Purine degradation produces uric acid, which is sparingly soluble and famously causes gout when it crystallizes in joints. Pyrimidine degradation produces β-alanine and β-aminoisobutyrate — highly water-soluble compounds that are easily excreted or metabolized. The clinical problems associated with pyrimidine catabolism are different (principally DPD deficiency causing 5-FU toxicity), not tissue accumulation of insoluble products.

Question 5

Why is DPD genotyping clinically important before administering 5-fluorouracil, and what is the biochemical basis for the toxicity risk?

Model answer: DPD (dihydropyrimidine dehydrogenase) is the rate-limiting enzyme in pyrimidine degradation and also the primary enzyme responsible for inactivating 5-FU — clearing approximately 80% of a standard dose. In patients with partial or complete DPD deficiency (a pharmacogenetic variant present in ~3-5% of people), this clearance is reduced or absent, causing 5-FU to accumulate far above therapeutic concentrations. At those elevated levels, 5-FU causes severe toxicity: myelosuppression, mucositis, neurotoxicity, and potentially death. Because the normal therapeutic dose assumes normal DPD activity, patients with deficiency require dramatically reduced doses or an alternative treatment. DPD genotyping identifies these patients before harm occurs.

This is a paradigmatic example of pharmacogenomics in oncology: a normal metabolic pathway intersects with drug metabolism in a clinically dangerous way. The same enzymatic machinery the body uses to clear dietary pyrimidines is co-opted to clear a cytotoxic drug, so a metabolic variant that is benign under normal conditions becomes life-threatening in the context of chemotherapy.